ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that ZOSTAVAX® (Zoster Vaccine Live), the company's
vaccine to help prevent shingles, received the Prix Galien USA 2013
Award for Best Biotechnology Product.
Language:
English
Contact:
Media:MerckCaroline Lappetito, (267) 305-7639
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Biotechnology | Drugs & Pharmacology | Merck | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine